What's new? Log in Free sign up

Nyxoah (NYXH)

Company Profile

Company profile

Ticker

NYXH

Exchange

Website

CEO

Mr. Olivier Taelman

Incorporated

Location

Fiscal year end

Sector

Health Care and Social Assistance > Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Stryker • FS KKR Capital • Boston Scientific • Solventum • Becton, Dickinson and • Blackstone Secured Lending Fund • Boardwalk Pipeline Partners • Domtar • Golub Capital BDC ...

Former names

GigCapital4, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NYXH stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Information on the total number of voting rights and shares

Current report (foreign)

Current report (foreign)

Registration of securities for employees

Nyxoah Reports Third Quarter Financial and Operating Results

Nyxoah Appoints John Landry as Chief Financial Officer

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

TOGETHER PARTNERSHIP

TOGETHER PARTNERSHIP

Gilde Healthcare Holding B.V.

Financial summary

Financial statements Chart NYXH financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Nyxoah earnings reports.

Institutional ownership, Q2 2023

NYXH institutional ownership history Ownership history

43.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	17	3	+466.7%
Opened positions	14	1	+1300.0%
Closed positions	0	18	EXIT
Increased positions	0	1	EXIT
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	20.31 bn	46.46 mm	+43616.8%
Total shares	12.45 mm	9.86 mm	+26.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Cochlear	5.09 mm	$34.62 mm	0.0%
Gilde Healthcare Holding B.V.	3.15 mm	$0.00	0.0%
RMD ResMed	1.62 mm	$11.84 mm	0.0%
BLK BlackRock	653.32 k	$5.23 bn	NEW
Deerfield Management	455.26 k	$3.65 bn	NEW
Opaleye Management	445.00 k	$3.56 bn	NEW
AXAHF Axa	217.00 k	$1.74 bn	NEW
Sio Capital Management	200.08 k	$1.60 bn	NEW
Putnam Investments	192.94 k	$1.58 bn	NEW
FMR	134.43 k	$1.10 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	653.32 k	+653.32 k	NEW
Deerfield Management	455.26 k	+455.26 k	NEW
Opaleye Management	445.00 k	+445.00 k	NEW
AXAHF Axa	217.00 k	+217.00 k	NEW
Sio Capital Management	200.08 k	+200.08 k	NEW
Putnam Investments	192.94 k	+192.94 k	NEW
FMR	134.43 k	+134.43 k	NEW
Rossmore Private Capital	117.94 k	+117.94 k	NEW
Pura Vida Investments	114.82 k	+114.82 k	NEW
DekaBank Deutsche Girozentrale	33.20 k	+33.20 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $17 Price Target

HC Wainwright & Co. analyst Edward White reiterates Nyxoah (NASDAQ:NYXH) with a Buy and maintains $17 price target.

Nyxoah's Genio Neuromodulation Therapy Debuts In England With First Implants At UCLH Under NHS Coverage

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London

Nyxoah Q3 EPS $(0.55) Misses $(0.46) Estimate, Sales $1.39M Miss $1.48M Estimate

Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 89.66 percent decrease over losses of $(0.29) per share from the same

Cantor Fitzgerald Reiterates Overweight on Nyxoah, Maintains $16 Price Target

HC Wainwright & Co. Maintains Buy on Nyxoah, Lowers Price Target to $17

Press releases

From Benzinga Pro

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA

Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 27, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.